Robertson Nicole M, Centner Connor S, Tejwani Vickram, Hossen Shakir, Karmali Dipan, Liu Sibei, Siddharthan Trishul
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Center for Global Non-Communicable Disease Research and Training, School of Medicine, Johns Hopkins University, Baltimore, MD.
University of Louisville School of Medicine, Louisville, KY; Department of Bioengineering, School of Engineering, University of Louisville, Louisville, KY.
Chest. 2025 Jun;167(6):1591-1614. doi: 10.1016/j.chest.2024.12.025. Epub 2024 Dec 30.
The prevalence of chronic respiratory diseases is increasing globally. There is evidence that those with spirometric impairment and no signs of obstruction (termed preserved ratio impaired spirometry [PRISm]) have an increased risk of morbidity and mortality compared with those with normal lung function. Several gaps remain in characterizing PRISm.
What are the prevalence, risk factors, and clinical outcomes associated with PRISm globally?
In this systematic review, a comprehensive search using MEDLINE, Web of Science, Cumulative Index to Nursing and Allied Health Literature, and Cochrane Central Register of Controlled Trials databases was conducted to include epidemiologic studies; there were no language or data restrictions. Two reviewers independently screened citations and shortlisted full-text articles according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, and data were extracted. Quality was assessed with the Effective Public Health Practice Project tool.
A total of 52 studies met the inclusion criteria, and 33 studies were included in the meta-analysis. Pooled PRISm prevalence was 12% (95% CI, 0.10-0.15) with greater prevalence in low- and middle-income countries (LMICs) compared with high-income countries (19% vs 11%). Comorbid diabetes was a significant risk factor associated with PRISm, but the data for female sex and smoking were mixed. PRISm was associated with increased all-cause (OR, 1.41; 95% CI, 1.08-1.83; P = .02), cardiovascular (OR, 1.84; 95% CI, 1.31-2.58; P < .01), and respiratory (OR, 1.82; 95% CI, 1.08-3.05; P = .03) mortality. PRISm was not associated with a reduced rate of lung cancer diagnosis (P = .46). Quality assessment analysis found that 34.6% (n = 18) of studies were rated "strong," 42.3% (n = 22) "moderate," and 23.1% (n = 12) "weak." Studies conducted in LMICs had lower quality ratings.
Our findings show that individuals with PRISm have an increased risk of all-cause, cardiovascular, and respiratory mortality. Recognizing and targeting modifiable PRISm risk factors may reduce the growing burden of PRISm and transition to obstructive lung disease globally. Additional studies in LMICs are needed to assess unique exposures and disease trajectories relevant to these populations.
慢性呼吸道疾病在全球的患病率正在上升。有证据表明,与肺功能正常者相比,存在肺量计测定受损但无气流受限迹象(称为肺量计比率保留性受损[PRISm])的人发病和死亡风险增加。在PRISm的特征描述方面仍存在一些空白。
全球范围内与PRISm相关的患病率、危险因素和临床结局是什么?
在这项系统评价中,通过使用MEDLINE、科学网、护理及相关健康文献累积索引和Cochrane对照试验中央注册库数据库进行全面检索,以纳入流行病学研究;没有语言或数据限制。两名审阅者根据系统评价和Meta分析的首选报告项目指南独立筛选引文并列出全文文章的入围清单,并提取数据。使用有效公共卫生实践项目工具评估质量。
共有52项研究符合纳入标准,33项研究纳入Meta分析。汇总的PRISm患病率为12%(95%CI,0.10 - 0.15),低收入和中等收入国家(LMICs)的患病率高于高收入国家(19%对11%)。合并糖尿病是与PRISm相关的一个重要危险因素,但关于女性和吸烟的数据存在混杂。PRISm与全因死亡率(OR,1.41;95%CI,1.08 - 1.83;P = 0.02)、心血管死亡率(OR,1.84;95%CI,1.31 - 2.58;P < 0.01)和呼吸死亡率(OR,1.82;95%CI,1.08 - 3.05;P = 0.03)增加相关。PRISm与肺癌诊断率降低无关(P = 0.46)。质量评估分析发现,34.6%(n = 18)的研究被评为“强”,42.3%(n = 22)为“中 ”,23.1%(n = 12)为“弱”。在LMICs进行的研究质量评级较低。
我们的研究结果表明,患有PRISm的个体全因、心血管和呼吸死亡率风险增加。识别并针对可改变的PRISm危险因素可能会减轻全球范围内PRISm不断增加的负担,并减少向阻塞性肺病的转变。需要在LMICs开展更多研究,以评估与这些人群相关的独特暴露因素和疾病轨迹。